Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06452446 · ClinicalTrials.gov registry record
Telehealth-based Symptom Management for Veterans Treated With Selinexor
A clinical trial of Multiple Myeloma and Large-cell Lymphoma, sponsored by Durham VA Medical Center.
- Active
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT06452446: Active study of Multiple Myeloma and Large-cell Lymphoma, sponsored by Durham VA Medical Center.
NCT06452446 is a study of Multiple Myeloma and Large-cell Lymphoma that is active but no longer recruiting, run by Durham VA Medical Center. The registered enrollment target is 20 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06452446, a study of Multiple Myeloma and Large-cell Lymphoma, is active but no longer recruiting, sponsored by Durham VA Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out if continued monitoring of side effects from Selinexor and prescribed medication to prevent side effects helps improve symptoms, quality of life, and ability to continue the treatment longer.
Primary Outcome
• VSAS: Veteran Symptom Assessment Scale (VSAS), a cancer symptom measurement tool.
Conditions Studied
Interventions
- DRUG Selinexor
Study Locations (1)
North Carolina
- Durham VA Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-09-01 |
| Est. Completion | 2028-07-01 |
What the registry record for NCT06452446 still lists
NCT06452446 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Selinexor is the first listed.
NCT06452446 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06452446 about?
NCT06452446 is a clinical study titled "Telehealth-based Symptom Management for Veterans Treated With Selinexor". The purpose of this study is to find out if continued monitoring of side effects from Selinexor and prescribed medication to prevent side effects helps improve symptoms, quality of life, and ability to continue the treatment longer.
What is the current status of trial NCT06452446?
This trial is currently active not recruiting. The enrollment target is 20 participants. The study started on 2024-09-01. Estimated completion is 2028-07-01.
What conditions does trial NCT06452446 study?
This clinical trial studies the following conditions: Multiple Myeloma, Large-cell Lymphoma.
What interventions are being tested in trial NCT06452446?
The interventions under investigation include: Selinexor (DRUG).
Who is sponsoring clinical trial NCT06452446?
This trial is sponsored by Durham VA Medical Center, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06452446 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06452446's enrollment target sits among peer trials
20 381st of 438 higher than 47 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
RECRUITING
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI